Revenue	1Q16	2Q16	3Q16E	4Q16E	FY16E	1QFY17E	2QFY17E	3QFY17E	4QFY17E	FY17E	1QFY18E	2QFY18E	3QFY18E	4QFY18E	FY18E	1QFY19E	2QFY19E	3QFY19E	4QFY19E	FY19
Molecular Diagnostics market share	0	0	0	0	0	0	0	1,957,941,144	1,957,941,144	7,831,764,575	2,087,165,259	2,087,165,259	2,087,165,259	2,087,165,259	8,348,661,037	2,224,918,166	2,224,918,166	2,224,918,166	2,224,918,166	8,899,672,665
Penetration rate by PSID(Firefly DX)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.02%	0.02%	0.04%	0.050%	0.080%	0.09%	0.07%	0.15%	0.16%	0.18%	0.20%	0.17%
Revenue from PCR market								195,794	391,588	587,382	834,866	1,043,583	1,669,732	1,878,449	5,426,630	3,337,377	3,559,869	4,004,853	4,449,836	15,351,935
Medical Devices(Thermomedics)	120,000	120,120	117,718	117,835	475,673	120,192	122,896	125,662	128,803	497,553	132,023	135,654	139,045	143,216	549,938	148,587	154,159	160,325	166,738	629,810
Mobile Labs(E-N-G Systems)	1,544,000	1,528,560	993,564	1,003,500	5,069,624	1,103,850	1,214,235	1,335,658	1,442,511	5,096,253	1,593,974	1,765,327	1,959,512	2,179,958	7,498,771	2,436,103	2,728,435	3,055,847	3,430,188	11,650,573
Total Revenue	**1,664,000**	**1,848,000**	**1,111,282**	**1,121,335**	**5,744,617**	**1,224,042**	**1,337,131**	**1,657,114**	**1,962,902**	**6,181,188**	**2,560,864**	**2,944,563**	**3,768,290**	**4,201,623**	**13,475,339**	**5,922,067**	**6,442,463**	**7,221,025**	**8,046,763**	**27,632,318**
Cost of revenues	1,135,000	1,212,000	733,446	751,294	3,831,740	795,627	869,135	1,043,982	1,236,628	3,945,372	1,587,735	1,825,629	2,336,340	2,520,974	8,270,678	3,494,019	3,672,204	4,043,774	4,425,720	15,635,717
Gross profit	**529,000**	**636,000**	**377,836**	**370,041**	**1,912,876**	**428,415**	**467,996**	**613,132**	**726,274**	**2,235,816**	**973,128**	**1,118,934**	**1,431,950**	**1,680,649**	**5,204,661**	**2,428,047**	**2,770,259**	**3,177,251**	**3,621,043**	**11,996,601**
Operating expenses:																				
Selling, general and administrative	1,826,000	1,787,000	944,589	897,068	5,454,657	1,040,435	1,002,848	1,242,835	1,472,176	**4,758,295**	1,536,518	1,619,510	1,884,145	2,100,811	**7,140,984**	2,961,033	3,221,232	3,249,461	3,621,043	13,052,770
Research and development	95,000	101,000	100,000	100,000	396,000	97,923	106,970	132,569	157,032	**494,495**	179,260	176,674	226,097	252,097	834,129	355,324	386,548	433,262	482,806	1,657,939
Total operating expenses	1,921,000	1,888,000	1,044,589	997,068	5,850,657	1,138,359	1,109,819	1,375,404	1,629,209	**5,252,790**	1,715,779	1,796,183	2,110,242	2,352,909	7,975,113	3,316,357	3,607,779	3,682,723	4,103,849	14,710,709
Operating income (loss)	**(1,392,000)**	**(1,252,000)**	**(666,754)**	**(627,027)**	**(3,937,781)**	**(709,944)**	**(641,823)**	**(762,272)**	**(902,935)**	**(3,016,974)**	**(742,650)**	**(677,249)**	**(678,292)**	**(672,260)**	**(2,770,452)**	**(888,310)**	**(837,520)**	**(505,472)**	**(482,806)**	**(2,714,108)**
Other income (expense):																				
Interest expense	(1,641,000)	(1,948,000)	(1,641,000)	(1,641,000)	**(6,871,000)**	(1,000,000)	(1,000,000)	(1,000,000)	(1,000,000)	**(4,000,000)**	(500,000)	(500,000)	(500,000)	(500,000)	**(2,000,000)**	(250,000)	(250,000)	(250,000)	(250,000)	(1,000,000)
Change in fair value of embedded conversion option liability	(937,000)	1,284,000	0	0	0	0	0	0	0	**0**	0	0	0	0	0	0	0	0	0	0
Loss on extinguishment of debt	0	0	0	0	0	0	0	0	0	**0**	0	0	0	0	0	0	0	0	0	0
Other income (expense), net	44,000	7,000	0	0	0	0	0	0	0	**0**	0	0	0	0	0	0	0	0	0	0
Total interest and other income (expense), net	(2,534,000)	(657,000)	(1,641,000)	(1,641,000)	(6,871,000)	(1,000,000)	(1,000,000)	(1,000,000)	(1,000,000)	**(4,000,000)**	(500,000)	(500,000)	(500,000)	(500,000)	(2,000,000)	(250,000)	(250,000)	(250,000)	(250,000)	(1,000,000)
Net loss	**(3,926,000)**	**(1,909,000)**	**(2,307,754)**	**(2,268,027)**	**(10,808,781)**	**(1,709,944)**	**(1,641,823)**	**(1,762,272)**	**(1,902,935)**	**(7,016,974)**	**(1,242,650)**	**(1,177,249)**	**(1,178,292)**	**(1,172,260)**	**(4,770,452)**	**(1,138,310)**	**(1,087,520)**	**(755,472)**	**(732,806)**	**(3,714,108)**
Preferred stock dividends	(33,000)	(33,000)																		
Net loss attributable to common stockholders	**(3,959,000)**	**(1,942,000)**	**(2,307,754)**	**(2,268,027)**	**(10,808,781)**	**(1,709,944)**	**(1,641,823)**	**(1,762,272)**	**(1,902,935)**	**(7,016,974)**	**(1,242,650)**	**(1,177,249)**	**(1,178,292)**	**(1,172,260)**	**(4,770,452)**	**(1,138,310)**	**(1,087,520)**	**(755,472)**	**(732,806)**	**(3,714,108)**
Net Loss per common share attributable to common stockholders – basic and diluted	(0.42)	(0.08)	(0.08)	(0.0653)	(0.44)	(0.04)	(0.03)	(0.03)	(0.03)	(0.13)	(0.02)	(0.02)	(0.02)	(0.02)	(0.07)	(0.02)	(0.02)	(0.01)	(0.01)	(0.05)
Weighted average shares outstanding – basic and diluted	9,390,502	24,129,091	28,954,909	34,745,891	24,305,098	45,169,658	56,462,073	59,285,177	62,842,287	55,939,799	65,984,402	68,623,778	68,623,778	69,996,253	68,307,052	70,696,216	70,696,216	70,696,216	70,696,216	70,696,216
YoY Revenue Growth					95%					8%					118%					105%
QoQ Revenue Growth	545%	0.50%	-10.00%	-5.00%		9.16%	9.24%	23.93%	18.45%		30.46%	14.98%	27.97%	11.50%						
Gross Margin	32%	34%	34%	33%	33%	35%	35%	37%	37%	36%	38%	38%	38%	40%	39%	41%	43%	44%	45%	43%
Operating Margin	-84%	-68%	-60%	-56%	-69%	-58%	-48%	-46%	-46%	-49%	-29%	-23%	-18%	-16%	-21%	-15%	-13%	-7%	-6%	-10%
G&A % of Rev	110%	90%	85%	80%	80%	85%	75%	75%	75%	80%	60%	55%	50%	50%	53%	50%	50%	45%	45%	47%
R&D % of Rev	6%	5%	9%	9%	7%	8%	8%	8%	8%	8%	7%	6%	6%	6%	6%	6%	6%	6%	6%	6%